Kintara Therapeutics 2024 Corporate Oncology Presentation

Kintara Therapeutics is a late-stage oncology company developing REM-001, a second-generation photodynamic therapy platform. The de-risked product candidate targets cutaneous metastatic breast cancer with FDA Fast Track designation, supported by extensive Phase 2/Phase 3 efficacy data and a 1,100+ patient safety database.